Subtype
Neuroblastoma
CI-CAN-00003408Explore in graph →
137 active trials3 approved drugs27 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003408Explore in graph →
Clinical trials
616 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (80)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00295919 | N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma | completed | Phase 1 | 80 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT00509353 | N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma | completed | Phase 1 | 26 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 14, 2026 |
| clinicaltrials |
| NCT00646230 | N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma(IV Fenretinide) | completed | Phase 1 | 17 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Apr 14, 2026 | clinicaltrials |
| NCT07518654 | Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma(ThINKK-01) | not yet recruiting | Phase 1 | 12 | Michel DuvalOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT01822652 | 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN(GRAIN) | active not recruiting | Phase 1 | 11 | Baylor College of MedicineOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07502287 | Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma(DUAL-NK-NB) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03721068 | Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | recruiting | Phase 1 | 18 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02298348 | Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma(N2013-02) | active not recruiting | Phase 1 | 18 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Mar 23, 2026 | clinicaltrials |
| NCT02573896 | Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells | active not recruiting | Phase 1 | 13 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT02780128 | Next Generation Personalized Neuroblastoma Therapy(NEPENTHE) | terminated | Phase 1 | 66 | Yael P MosseOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02909777 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07399821 | An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma(GLOW-FISH) | recruiting | Phase 1 / Phase 2 | 22 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT01175356 | Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin | completed | Phase 1 | 99 | Children's Oncology GroupNETWORK | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07334301 | A Multi-Arm, Platform Trial For Relapsed Neuroblastoma(BEACON2) | recruiting | Phase 1 / Phase 2 | 160 | University of BirminghamOTHER | 5 | Jan 12, 2026 | clinicaltrials |
| NCT00085930 | Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients(NESTLES) | completed | Phase 1 | 19 | Baylor College of MedicineOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT01757626 | Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma | active not recruiting | Phase 1 / Phase 2 | 186 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05400603 | Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma(Aflac-NBL-2002) | recruiting | Phase 1 | 24 | Emory UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06803875 | Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma | recruiting | Phase 1 / Phase 2 | 42 | Roberto ChiarleOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT05429502 | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | terminated | Phase 1 | 12 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 10, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT03294954 | GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma(GINAKIT2) | recruiting | Phase 1 | 70 | Baylor College of MedicineOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04023331 | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma | terminated | Phase 1 / Phase 2 | 21 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT03107988 | NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) | completed | Phase 1 | 65 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 4 | Sep 15, 2025 | clinicaltrials |
| NCT02650648 | Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | completed | Phase 1 | 85 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06485947 | Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma(DBPilot) | recruiting | Phase 1 | 38 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT00703222 | A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells(CHESAT) | completed | Phase 1 / Phase 2 | 7 | Baylor College of MedicineOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06948994 | A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma | not yet recruiting | Phase 1 / Phase 2 | 15 | Guangzhou Women and Children's Medical CenterOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT03332667 | MIBG With Dinutuximab +/- Vorinostat | completed | Phase 1 | 45 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06674265 | Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma | recruiting | Phase 1 | 10 | Marzieh EbrahimiINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | terminated | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06836505 | Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. | recruiting | Phase 1 / Phase 2 | 10 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06631391 | Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma. | recruiting | Phase 1 | 30 | Sun Yat-sen UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT02030964 | N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan(DFMO) | completed | Phase 1 | 30 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 3 | Feb 17, 2025 | clinicaltrials |
| NCT01868490 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells | enrolling by invitation | Phase 1 / Phase 2 | 20 | Siriraj HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06751134 | Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma | recruiting | Phase 1 | 12 | Nanjing Children's HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03373097 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT02076906 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | completed | Phase 1 | 7 | AeRang KimOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT00002730 | Chemotherapy in Treating Children With Neuroblastoma | completed | Phase 1 | — | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT00867568 | TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma | completed | Phase 1 | 18 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01059071 | Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide | completed | Phase 1 | 21 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01483820 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | terminated | Phase 1 / Phase 2 | 8 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01505608 | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma | terminated | Phase 1 / Phase 2 | 14 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02630043 | Trial of Tolcapone With Oxaliplatin for Neuroblastoma | terminated | Phase 1 | 5 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Apr 14, 2026source: clinicaltrials